Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus

RT Ross; MR Dawood; Mary Cheang; Lindsay E Nicolle

doi:10.1155/1996/417061

Canadian Journal of Infectious Diseases (Jan 1996)

Antibody Response in Seropositive Multiple Sclerosis Patients Vaccinated with Attenuated Live Varicella Zoster Virus

RT Ross,
MR Dawood,
Mary Cheang,
Lindsay E Nicolle

Affiliations

RT Ross: Section of Neurology, University of Manitoba, Winnipeg, Manitoba, Canada
MR Dawood: Infectious Diseases and Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Mary Cheang: Biostatistical Consulting Unit Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Lindsay E Nicolle: Infectious Diseases and Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

DOI: https://doi.org/10.1155/1996/417061
Journal volume & issue: Vol. 7, no. 5
pp. 303 – 306

Abstract

Read online

OBJECTIVE: To determine the safety and effectiveness of live attenuated varicella zoster virus (VZV) vaccine (OKA/Merck) on 50 patients with chronic progressive multiple sclerosis (MS), based on the hypothesis that VZV might be the antigen or antigen mimic of MS plus the fact that repeated high antigen doses have produced ‘antigen paralysis’ in experimental allergic encephalomyelitis mice.

Published in Canadian Journal of Infectious Diseases

ISSN: 1180-2332 (Print)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases
Website: https://onlinelibrary.wiley.com/journal/9575

About the journal